Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Forensic Toxicology
Published in: Forensic Toxicology 2/2018

Open Access 01-07-2018 | Original Article

Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds

Authors: Clara T. Schoeder, Cornelius Hess, Burkhard Madea, Jens Meiler, Christa E. Müller

Published in: Forensic Toxicology | Issue 2/2018

Login to get access

Abstract

Purpose

In the present study we characterized a series of synthetic cannabinoids containing various heterocyclic scaffolds that had been identified as constituents of “Spice”, a preparation sold on the illicit drug market. All compounds were further investigated as potential ligands of the orphan receptors GPR18 and GPR55 that interact with some cannabinoids.

Methods

The compounds were studied in radioligand binding assays to determine their affinity for human cannabinoid CB1 and CB2 receptors expressed in CHO cells, and in cAMP accumulation assays to study their functionality.

Results

Structure-activity relationships were analyzed. The most potent CB1 receptor agonist of the present series MDMB-FUBINACA (12) (Ki = 98.5 pM) was docked into the human CB1 receptor structure, and a plausible binding mode was identified showing high similarity with that of the co-crystallized THC derivatives. MDMB-CHMCZCA (41) displayed a unique profile acting as a full agonist at the CB1 receptor subtype, but blocking the CB2 receptor completely. Only a few weakly potent antagonists of GPR18 and GPR55 were identified, and thus all compounds showed high CB receptor selectivity, mostly interacting with both subtypes, CB1 and CB2.

Conclusions

These results will be useful to assess the compounds’ toxicological risks and to guide legislation. Further studies on 41 are warranted.
Appendix
Available only for authorised users
Literature
1.
Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58–63CrossRefPubMed
2.
3.
4.
Davidson C, Opacka-Juffry J, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, Molina-Holgado F (2017) Spicing up pharmacology. Adv Pharmacol 80:135–168CrossRefPubMed
5.
6.
Fredriksson R, Lagerstrom MC, Lundin L-G, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272CrossRefPubMed
7.
Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101–106CrossRefPubMed
8.
Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251CrossRefPubMed
9.
10.
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583CrossRefPubMed
11.
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65CrossRefPubMed
12.
Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631CrossRefPubMedPubMedCentral
13.
Miller AM, Stella N (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153:299–308CrossRefPubMed
14.
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215CrossRefPubMed
15.
Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30 Suppl 1:13–18CrossRef
16.
Riederer AM, Campleman SL, Carlson RG, Boyer EW, Manini AF, Wax PM, Brent JA (2016) Acute poisonings from synthetic cannabinoids—50 U.S. Toxicology Investigators Consortium Registry Sites, 2010–2015. MMWR Morb Mortal Wkly Rep 65:692–695CrossRefPubMedPubMedCentral
17.
18.
Bundesministerium der Justiz und für Verbraucherschutz (2016) Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe. BGBl I Nr. 55
19.
Bundesministerium für Verfassung, Reformen, Deregulierung und Justiz (2011) Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen. BGBl. I Nr. 146/2011
20.
Die Bundesversammlung der Schweizerischen Eidgenossenschaft (2011) Bundesgesetz über die Betäubungsmittel und die psychotropen Stoffe. SR 812.121
21.
Huffman JW, Dai D, Martin BR, Compton DR (1994) Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 4:563–566CrossRef
22.
Huffman JW, Zengin G, Wu M-J, Lu J, Hynd G, Bushell K, Thompson ALS, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR (2005) Structure–activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg Med Chem 13:89–112CrossRefPubMed
23.
Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRef
24.
Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837CrossRefPubMed
25.
Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016) Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol 34:329–343CrossRefPubMedPubMedCentral
26.
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101CrossRefPubMedPubMedCentral
27.
McHugh D, Page J, Dunn E, Bradshaw HB (2012) Δ9-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165:2414–2424CrossRefPubMedPubMedCentral
28.
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817–29827CrossRefPubMedPubMedCentral
29.
Rempel V, Atzler K, Behrenswerth A, Karcz T, Schoeder C, Hinz S, Kaleta M, Thimm D, Kiec-Kononowicz K, Müller CE (2014) Bicyclic imidazole-4-one derivatives as: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55. Med Chem Commun 5:632–649CrossRef
30.
Nordstedt C, Fredholm BB (1990) A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189:231–234CrossRefPubMed
31.
Bender BJ, Cisneros A 3rd, Duran AM, Finn JA, Fu D, Lokits AD, Mueller BK, Sangha AK, Sauer MF, Sevy AM, Sliwoski G, Sheehan JH, DiMaio F, Meiler J, Moretti R (2016) Protocols for molecular modeling with Rosetta3 and RosettaScripts. Biochemistry 55:4748–4763CrossRefPubMedPubMedCentral
32.
Kaufmann KW, Lemmon GH, Deluca SL, Sheehan JH, Meiler J (2010) Practically useful: what the Rosetta protein modeling suite can do for you. Biochemistry 49:2987–2998CrossRefPubMedPubMedCentral
33.
Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho J-H, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu Z-J (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468–471CrossRefPubMedPubMedCentral
34.
35.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612CrossRefPubMed
36.
Fujioka M, Omori N (2012) Subtleties in GPCR drug discovery: a medicinal chemistry perspective. Drug Discov Today 17:1133–1138CrossRefPubMed
37.
Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrick RE, Wu KK (2009) Indazole derivatives. WO 2009/106982/A1
38.
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JBC, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254CrossRefPubMed
39.
Adamowicz P (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 261:e5–e10CrossRefPubMed
40.
Bäckberg M, Tworek L, Beck O, Helander A (2017) Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol 13:52–60CrossRefPubMed
41.
Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF (2015) AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing Δ9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 354:328–339CrossRefPubMedPubMedCentral
42.
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M (2015) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6:1546–1559CrossRefPubMed
43.
Bowden MJ, Williamson JPB (2014) Cannabinoid compounds. WO2014/167530/A1
44.
Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115CrossRef
45.
46.
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644–650PubMed
47.
Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126:665–672CrossRefPubMedPubMedCentral
48.
Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, Rosenbaum DM (2016) High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature 540:602–606CrossRef
49.
Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, Laprairie RB, Stahl EL, Ho J-H, Zvonok N, Zhou H, Kufareva I, Wu B, Zhao Q, Hanson MA, Bohn LM, Makriyannis A, Stevens RC, Liu Z-J (2016) Crystal structure of the human cannabinoid receptor CB1. Cell 167:750–762CrossRefPubMedPubMedCentral
50.
Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R (2017) “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 376:235–242CrossRefPubMed
51.
Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, Kassiou M (2017) Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chem Neurosci 8:2159–2167CrossRefPubMed
52.
Rempel V, Volz N, Hinz S, Karcz T, Meliciani I, Nieger M, Wenzel W, Bräse S, Müller CE (2012) 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J Med Chem 55:7967–7977CrossRefPubMed
53.
Rempel V, Fuchs A, Hinz S, Karcz T, Lehr M, Koetter U, Müller CE (2013) Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55. ACS Med Chem Lett 4:41–45CrossRefPubMed
Metadata
Title
Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds
Authors
Clara T. Schoeder
Cornelius Hess
Burkhard Madea
Jens Meiler
Christa E. Müller
Publication date
01-07-2018
Publisher
Springer Japan
Published in
Forensic Toxicology / Issue 2/2018
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI
https://doi.org/10.1007/s11419-018-0415-z

Other articles of this Issue 2/2018

Forensic Toxicology 2/2018 Go to the issue

Letter to the Editor

Pentobarbital use in a decomposed suicide

Original Article

The internal standard diquat-d4 causes errors in diquat analysis by LC–MS/MS

Review Article

Diphenidine: a dissociative NPS makes an entrance on the drug scene

Case Report

Toxicological and histological analyses for a stillborn delivered by a mother under methadone maintenance therapy

Original Article

VOCs as fingerprints for the chemical profiling of hashish samples analyzed by HS-SPME/GC–MS and multivariate statistical tools

Original Article

Differentiation of AB-FUBINACA and its five positional isomers using liquid chromatography–electrospray ionization-linear ion trap mass spectrometry and triple quadrupole mass spectrometry